Soluble tumor necrosis factor receptor-1 tied to decline in multiethnic cohort
THURSDAY, Oct. 4, 2018 (HealthDay News) — High circulating levels of an inflammatory marker, soluble tumor necrosis factor receptor-1 (sTNFR-1), are linked to long-term decline of kidney function, according to a study published online Oct. 4 in the Journal of the American Society of Nephrology.
Pavan K. Bhatraju, M.D., from the University of Washington in Seattle, and colleagues evaluated associations between baseline sTNFR-1 concentrations and 10-year decline in estimated glomerular filtration rate (eGFR) among 2,548 participants in the Multi-Ethnic Study of Atherosclerosis. Serum creatinine concentrations were measured at enrollment and at three, five, and 10 years.
The researchers found that serum sTNFR-1 was inversely associated with baseline eGFR. During a median of 9.3 years of follow-up, 110 participants developed ≥40 percent decline in eGFR. Each standard deviation higher concentration of sTNFR1 was associated with a higher risk of 40 percent eGFR decline (adjusted hazard ratio, 1.43). There was an association between the highest sTNFR-1 tertile and adjusted annualized decline in eGFR (1.94 percent). Results were similar across demographics, hypertension, diabetes, and baseline chronic kidney disease status.
“Our studies identify a novel marker that is strongly related to kidney function decline over time in a large multi-ethnic cohort and suggest follow up studies are warranted to investigate the potential role of sTNFR-1 in the development of kidney function decline,” Bhatraju said in a statement.
Copyright © 2018 HealthDay. All rights reserved.
